Tetrahedron, Vol. 52, No. 32, pp.

10823q0826, 1996
Pergamon Copyright © 1996 Elsevier Science Ltd
Printed in Great Britain. All fights reserved
0040-4020/96 $15.00 + 0.00
PII: S0040-4020(96)00603-5

Solid-Phase Synthesis of Substituted 1,2,3-Triazoles

Florencio Zaragoza* and Susanne Vejle Petersen

Novo Nordisk A/S, Novo Nordisk Park, DK-2760 M~lCv, Denmark

Telefax: (+45) 4466 3450, e-mail: [email protected]

Abstract: Diversely substituted 1,2,3-triazoles have been synthesized on a solid support. A resin-bound
3-oxobutyramide could be effectively condensed with primary aliphatic amines. Theresulting 3-amino-2-
butenoic acid amides were then cyclized by treatment with tosyl azide in the presence of a tertiary
amine. Acidolytie cleavage from the support yielded the corresponding 1,2,3-triazoles in purities up to
82% (HPLC). Copyright© 1996 ElsevierScienceLtd

Combinatorial chemistry is becoming increasingly important in pharmaceutical research as an efficient

tool for the rapid identification and optimization of new leads? Solid-phase synthesis is playing a decisive role
in the ongoing development of combinatorial chemistry, mainly because it offers high synthetic flexibility as
well as the possibility of automatization. However, the number of different reactions applicable to solid-phase
synthesis, although rapidly growing, is still small, if compared to the vast repertoire of synthetic methodology
available for synthesis "in solution". In particular, the access to heterocyclic compounds by solid-phase
synthesis2 is urgently required, since small, substituted heterocycles offer a high degree of structural diversity
and have proven to be exceptionally useful in many applications. 6
In this communication a new synthetic sequence is presented, which allows the solid-phase synthesis
of substituted 1,2,3-triazoles (see scheme). While investigating the chemistry of the support-bound (3-
oxobutyryl)piperazine 13 we found, that a condensation with primary, aliphatic amines readily occurred in the
presence of triethyl orthoformate. 4 The resulting 3-amino-2-butenoic acid amides 2a-c could successively be
cyclized to give the 1,2,3-triazoles 3a-e by treatment with tosyl azide and a tertiary amine.5 Treatment of these
resin-bound 1,2,3-triazoles 3a-c with trifluoroacetic acid in dichloromethane, followed by removal of the
solvents, yielded the crude triazoles 4a-c as trifluoroacetates in purities up to 82% (1H NMR, HPLC).
The mild reaction conditions used in this synthetic sequence enabled its application to building blocks
with a large number of different functionalities. Only when electron-rich benzylic amines, such as
benzhydrylamine, were used in the enamine-forming step, mixtures of products were obtained. This may be
due to the high stability of the corresponding benzylic carbocations, which could give rise to solvolysis of the
initially formed triazoles during the acidolytic cleavage.

10823
10824 F. ZARAGOZAand S. V. Pe.rERSEN

O O

ps o'kN RNH2 ps o-lLN-

L..N
DMF, HC(OEt)3
0 o O NHR
I 2a (R = CH2CO2CH2Ph )
2b (R = 4-methoxybenzyl)
2¢ [R = 2-(4,-nitrophenyl)ethyl]

TsN 3
IP
DMF, DIPEA

O • CF3CO2H O
3a-¢ 4a-c

Abbreviations: PS: polymeric support (polystyrene with Wang linker); TsN3: p-toluenesulfonyl azide; DIPEA:
diisopropylethylamine; TFA: trifluoroacetic acid.

In conclusion, a solid-phase protocol for the synthesis of 1,2,3-triazoles with in principle three
independently variable substituents is disclosed herein. Although only the conversion of the resin-bound (3-
oxobutyryl)piperazine 1 into different triazoles has been described here, this sequence may also be applicable
to other resin-bound amines (e.g. o~-amino acids, other diamines or resins with a Rink linker) and to other 3-
oxoalkanoic acids, thus permitting the fast and easy preparation of numerous, highly diverse non-oligomeric
compounds as potential drug candidates. 6

EXPERIMENTAL

General procedures. Wang resin (p-benzyloxybenzylalcoholresin) with a substitution of 0.94 mmol/g

was purchased from Calbiochem-Novabiochem AG. Reactions on solid support were carried out in arrays of
disposable polypropylene columns (20 mL, "Econo-Pac TM columns") from Bio-Rad Laboratories GmbH. These
columns were vortexed with a mechanical shaker (IKA-VibraxTM VXR, IKA Labortechnik GmbH) and
connected via polypropylene tubing to an evacnable filtering flask. The columns were closed with septa and
reagents were added through a needle with a syringe or a pipette (Finnpipette digitalTM, Labsystems Oy.).

Preparation of resin-bound (3-oxobutyryl)piperazine 1. To a suspension of Wang resin (45.0 g, 42.3

mmol) in dichloromethane (DCM, 600 mL) first pyridine (52 mL) and then a solution of 4-nitrophenyl
chloroformate (43.0 g, 231 mmol) in DCM (200 mL) were added. After stirring for 3 h at room temperature
the mixture was filtered, the resin was washed with DCM (5 x 300 mL) and then added to a cold solution of
 Substituted 1,2,3-triazoles 10825

piperazine (38.2 g, 444 retool) in DMF (600 mL). The resulting mixture was stirred for 13 h, filtered and the
resin was washed extensively with DMF, DCM and methanol. After drying, approx. 45 g of resin-bound
piperazine was obtained.
To a suspension of this resin (0.60 g, approx. 0.6 retool) in DMF (4 mL) a freshly prepared solution
of 3-oxobutyric acid phenyl ester7 (5 equivalents, prepared by refluxing a solution of phenol and 2,2,6-
trimethyl-l,3-dioxin-4-one in toluene for 1 h and used without isolation) in toluene (6 mL) was added,
followed by the addition of diisopropylethylamine (2 mL). The resulting mixture was shaken for 2 h, filtered,
the resin was washed with DMF and the acylation was then repeated once as described above for 3 h. Washing
with DMF yielded the resin-bound (3-oxobutyryl)piperazine 1, which was used for the following reactions
without drying.

General procedure for the solid-phase synthesis of 1H-1,2,3-triazole-4-carboxylic acid amides. To the
resin-bound 3-oxobutyramide 1 (prepared as described above from 0.60 g of resin-bound piperazine; approx.
0.6 mmol) a solution of the primary amine (3.0 mmol) in DMF (4 mL) was added, followed by the addition
of triethyl orthoformate (4 mL). The resulting mixture was shaken for 24 h and then filtered. The resin was
washed with DMF (2 x 10 mL) and then a solution of p-toluenesulfonyl azide (0.60 mL, 3.84 mmol) in DMF
(6 mL) was added to the resin, followed by the addition of diisopropylethylamine (2 mL). After shaking for
24 h the mixture was filtered and carefully washed with DMF, methanol, DCM and 10% AcOH in DCM. It
was then suspended in a solution of 60% TFA in DCM (8 mL) and shaken for 3 h. Filtration, washing with
DCM and concentration of the combined filtrates gave the crude triazoles 4a-c as oils.

[5-Methyl-4-(piperazine- l-carbonyl )- l H- l ,2,3-triazol- l-yl ]acetic acid benzyl ester trifluo roac etate (4a).
HPLC (Lichrosorb RP 18, acetonitrile/water gradient, monitoring at 254 nm): elution at 13.3 min, 65% pure.
tH NMR (400 MHz, DMSO-d6) ~ 2.34 (s, 3H), 3.20 (m, 4H), 3.82 (m, 2H), 4.18 (m, 2H), 5.21 (s, 2H), 5.57
(s, 2H), 7.39 (s, br, 5H), 8.99 (s, br, 2H). For analytical purposes, this compound was derivatized by
conversion into the corresponding 2-tolylurea by reaction with 2-methylphenyl isocyanate. The triazole
obtained from 0.60 g of starting Wang resin gave 201 mg (70%) of the 2-tolylurea. Colourless solid, m.p. 125-
127 °C (AcOEt). Anal. Calcd. for C25H~N604 (476.53): C, 63.01; H, 5.92; N, 17.64. Found: C, 62.93; H, 6.06;
N, 17.10.

[l-( 4-Methoxybenzyl )-5-methyl- l H-1,2,3-triazol-4-yl ]piperazin- l-ylmethanone trifluoroacetate (4b).

HPLC (Lichrosorb RP 18, acetonitrile/water gradient, monitoring at 254 nm): elution at 10.3 min, 52% pure.
~H NMR (400 MHz, DMSO-d6) 5 2.37 (s, 3H), 3.20 (m, 4H), 3.72 (s, 3H), 3.80 (m, 2H), 4.17 (m, 2H), 5.55
(s, 2H), 6.92 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 8.93 (s, br, 2H). For analytical purposes, this
compound was derivatized by conversion into the corresponding 4-chlorophenylurea by reaction with 4-
chlorophenyl isocyanate. The triazole obtained from 1.20 g of starting Wang resin gave 190 mg (34%) of the
4-chlorophenylurea. Colourless solid, m.p. 202-204 °C (AcOEt). Anal. Calcd. for C23HzsC1N603 (468.94): C,
58.91; H, 5.37; N, 17.92. Found: C, 59.03; H, 5.45; N, 17.72.

{5-Methyl-•-[2-(4•nitr•phenyl)ethy••-111-••2•3-triaz•l-4-yl•piperazin-•-ylmethan•ne trifluoroacetate (4e).

Yield of crude trifluoroacetate: 75%. HPLC (Lichrosorb RP 18, acetonitrile/water gradient, monitoring at 254
nm): elution at 14.6 min, 82% pure. 1H NMR (400 MHz, DMSO-d6) 8 2.37 (s, 3H), 3.15 (m, 4H), 3.30 (t, J
10826 F. ZARAGOZAand S. V. PETERSEN

= 7.0 Hz, 21-1), 3.82 (m, 2H), 4.15 (m, 2H), 4.64 (t, J = 7.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 8.13 (d, J =
8.0 Hz, 2H), 9.01 (s, br, 2H). For analytical purposes, this compound was derivatized by conversion into the
corresponding acetamide by reaction with acetic anhydride. The resulting product was identical to the
compound obtained from 1-acetylpiperazine by acetoacetylation, 7 condensation with 2-[4-
(nitrophenyl)]ethylamine and cyclization by treatment with p-toluenesulfonyl azide and triethylamine.
Colourless solid, m.p. 142-144 °C (AcOEt). Anal. Calcd. for CmHmN~O, (386.41): C, 55.95; H, 5.74; N, 21.74.
Found: C, 56.13; H, 5.93; N, 21.28.

REFERENCES AND NOTES

1. Terrett, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J. Tetrahedron 1995, 51, 8135-
8173; Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gordon, E. M. J. Med. Chert
1994, 37, 1233-1251; idem, J. Med. Chem- 1994, 37, 1385-1401.
2. Ruhland, B.; Bhandari, A.; Gordon, E. M.; Gallop, M. A. J. Am. Chem- Soc. 1996, 118, 253-254;
Friichtel, J. S.; Jung, G. Angew. Chert Int. Ed. Engl. 1996, 35, 17-42; Marzinzik, A. L.; Felder, E. R.
Tetrahedron Lett. 1996, 37, 1003-1006; Dressman, B. A.; Spangle, L. A.; Kaldor, S. W. Tetrahedron
Lett. 1996, 37, 937-940; Kaljnste, K.; Und6n, A. Tetrahedron Lett. 1995, 36, 9211-9214; Meutermans,
W. D. F.; Alewood, P. F. Tetrahedron Lett. 1995, 36, 7709-7712; Wipf, P.; Cunningham, A.
Tetrahedron Lett. 1995, 36, 7819-7822; Hiroshige, M.; Hauske, J. R.; Zhou, P. J. Am- Chem. Soc.
1995, 117, 11590-11591; Plunkett, M. J.; Ellman, J. A. J. Art Chem- Soc. 1995, 117, 3306-3307;
Steele, J.; Gordon, D. W. Bioorg.& Med. Chem- Lett. 1995, 5, 47-50; Murphy, M. M.; Schullek, J. R.;
Gordon, E. M.; Gallop, M. A. J. Am- Chem. Soc. 1995, 117, 7029-7030; Beebe, X.; Schore, N. E.;
Kurth, M. J. J. Org. Chem. 1995, 60, 4196-4203; Goff, D. A.; Zuckermann, R. N. J. Org. Chem- 1995,
60, 5744-5745; Boojamra, C. G.; Burow, K. M.; Ellman, J. A. J. Org. Chem- 1995, 60, 5742-5743;
Patek, M.; Drake, B.; Lebl, M. Tetrahedron Lett. 1995, 36, 2227-2230; Beebe, X.; Chiappari, C. L.;
Olmstead, M. M.; Kurth, M. J.; Schore, N. E. J. Org. Chert 1995, 60, 4204-4212; Goff, D. A.;
Zuckermann, R. N. J. Org. Chert 1995, 60, 5748-5749; Pei, Y. H.; Moos, W. H. Tetrahedron Lett.
1994, 35, 5825-5828; ApSimon, J. W.; Dixit, D. M. Can. J. Chem. 1982, 60, 368-370.
3, Zaragoza, F. Tetrahedron Letr 1995, 36, 8677-8678.
4. Look, G. C.; Murphy, M. M.; Campbell, D. A.; Gallop, M. A. Tetrahedron Lett. 1995, 36, 2937-2940.
5. Augusti, R.; Kascheres, C. Tetrahedron, 1994, 50, 6723-6726; idem J. Org. Chem., 1993, 58, 7079-
7083; Gordeev, M. F.; Komkov, A. V.; Bogdanov, V. S.; Dorokhov, V. A. Izv. Akad. Naulc SSSR, Ser.
Khim-, 1990, 1392-1397; Chakrasali, R. T.; Ila, H.; Junjappa, H. Synthesis, 1988, 851-854; Regitz, M.
Angew. Chem. 1965, 77, 735.
6. For the use of 1,2,3-tfiazoles as pharmaceuticals, see e.g. Kelley, J. L.; Koble, C. S.; Davis, R. G.;
Mclean, E. W.; Soroko, F. E.; Cooper, B. R. J. Med. Chem- 1995, 38, 4131-4134; Moltzen, E. K.;
Pedersen, H.; Bogeso, K. P.; Meier, E.; Frederiksen, K.; Sanchez, C.; Lembol, H. L. J. Med. Cheat
1994, 37, 4085-4099; Meier, R. Cheat Abstr. 1987, 106, 156480z; Chert Abstr. 1984, 101, 230539r.
7. Clemens, R. J.; Hyatt, J. A. J. Org. Chem- 1985, 50, 2431-2435.

(Received in UK 17 June 1996; accepted 26 June 1996)